pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Hepatology · news · pharmadog
← back to Hepatology
News · Hepatology
262
stories
Oct 13, 26
Merck KGaA spinout iOnctura touts PI3K delta inhibitor in metastatic eye cancer
fiercebiotech
Oct 13, 26
Roche expands obesity R&D footprint with Rona deal worth $1B+
biospace
Oct 13, 26
Pfizer pens $500M+ deal with Enodia to destroy disease-causing proteins
biospace
Oct 13, 26
Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race
fiercebiotech
Oct 12, 26
Bristol Myers dips on ‘confounding’ lung drug results
biopharma dive
Oct 12, 26
Mirum succeeds in rare liver disease trial; First Tracks delivers in celiac
endpoints
Oct 12, 26
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
Oct 12, 26
Undecimal Bio launches with $18M to take siRNA beyond liver disease
endpoints
Oct 12, 26
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
Oct 8, 26
Opinion: England and other nations are on the path toward eliminating hepatitis C. Why not the U.S.?
stat
Oct 7, 26
Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
biospace
Oct 7, 26
5 biggest venture capital raises of Q3 2026
biospace
Oct 6, 26
The top biopharma conferences in 2027
biopharma dive
Oct 6, 26
In this hospital, pulse oximeters went from overestimating to underestimating blood oxygen. Why?
stat
Oct 6, 26
TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
fiercebiotech
Oct 5, 26
CSL strikes up to $1.6B deal with Alentis for autoimmune drug with broad potential
biospace
Oct 5, 26
CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drug
fiercebiotech
Oct 5, 26
CSL to pay $355M upfront to co-develop Alentis’ kidney and liver drug
endpoints
Oct 2, 26
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Oct 2, 26
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
biospace
Oct 2, 26
STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
stat
Oct 1, 26
BMS reports liver injury events in lung disease program, with key readout near
biospace
Oct 1, 26
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
Oct 1, 26
Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken
fiercebiotech
Oct 1, 26
Opinion: I studied GLP-1 use in children. The results are reassuring
stat
Oct 1, 26
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
Sep 30, 26
Patient death raises liver questions ahead of Bristol Myers readout
endpoints
Sep 30, 26
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
biopharma dive
Sep 30, 26
FDA starts review of Roche’s multiple sclerosis pill
biopharma dive
Sep 30, 26
GSK continues to stock up on Wave's RNA drugs with liver-focused program
fiercebiotech
← prev
page 3 of 9
next →